venetoclax
ASTX727 is an oral fixed-dose combination of HMA decitabine and cytidine deaminase inhibitor cedazuridine...
New research suggests venetoclax-containing regimens with intensive treatment and may improve outcomes.
Alexandre Bazinet, MD, and colleagues conducted the single-center, dose-expansion phase I/II trial...
Advertisement
The European Commission has granted Marketing Authorization for the expanded use of ibrutinib.
The analysis results have clinical implications, as venetoclax-based regimens are the standard of care for patients.
Of 23 patients, three achieved complete remission and 15 achieved complete remission with incomplete hematological recovery.
Advertisement
Three-year follow-up data from the CAPTIVATE trial were presented at the 2022 ASCO Annual Meeting.
The study included adults with treatment-naïve and relapsed/refractory CLL or small lymphocytic leukemia.
The results did not provide any clear benefit by adding venetoclax in patients with previously untreated follicular lymphoma.
The triplet combination resulted in a composite complete remission rate of 91%.
This article reviews the proposed mechanisms of action of venetoclax in AML and the potential future of venetoclax in AML.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.